Hematopoiesis News Volume 14.26 | Jul 04 2023

    By
    Jamie Kang
    -
    0
    16







    2023-07-04 | HN 14.26


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.26 – 4 July, 2023
    TOP STORY

    Potent and Uniform Fetal Hemoglobin Induction via Base Editing

    Inducing fetal hemoglobin in red blood cells can alleviate β-thalassemia and sickle cell disease. Investigators compared five strategies in CD34+ hematopoietic stem and progenitor cells, using either Cas9 nuclease or adenine base editors.
    [Nature Genetics]

    AbstractPress Release
    Image of erythroblasts which were simply & efficiently generated from PSCs using the STEMdiff Erythroid Kit.
    PUBLICATIONSRanked by the impact factor of the journal

    Controlling Genetic Heterogeneity in Gene-Edited Hematopoietic Stem Cells by Single-Cell Expansion

    Researchers presented an approach for expanding gene-edited hematopoietic stem cells at clonal density, allowing for genetic profiling of individual clones before transplantation.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    Pharmacological GLUT3 Salvage Augments the Efficacy of Vitamin C-Induced TET2 Restoration in Acute Myeloid Leukemia

    In vitro GLUT3 restoration was conducted with the transduction of GLUT3-overexpressing lentivirus or the pharmacological salvage with 5-aminoimidazole-4-carboxamide ribonucleotide treatment to OCI-AML3, a naturally GLUT3-deficient AML cell line.
    [Leukemia]

    Abstract

    MCL1 Regulates Aml Cells Metabolism via Direct Interaction with HK2. Metabolic Signature at Onset Predicts Overall Survival in AMLs’ Patients

    Researchers characterized the metabolic background in distinct AMLs, by comparing the metabolism of primary AML blasts isolated at diagnosis with that of normal hematopoietic maturing progenitors, using the Seahorse XF Agilent.
    [Leukemia]

    Abstract

    Lymphocyte Migration and Retention Properties Affected by Ibrutinib in Chronic Lymphocytic Leukemia

    To explore the mechanism of action of ibrutinib and its potential impact on non-leukemic cells, investigators quantified multiple motility and adhesion parameters of human primary chronic lymphocytic leukemia cells and non-leukemic lymphoid cells.
    [Haematologica]

    Abstract

    Short-Term Immune-Checkpoint Inhibition Partially Rescues Perturbed Bone Marrow Hematopoiesis in Mismatch-Repair Deficient Tumors

    Using anti-PD1 and anti-LAG-3 Immune-checkpoint inhibitor treatments, researchers investigated the effect of bone marrow hematopoiesis in tumor-bearing Msh2loxP/loxP;TgTg(Vil1-cre) mice.
    [Oncoimmunology]

    Full ArticleGraphical Abstract

    Isoforms of the TAL1 Transcription Factor Have Different Roles in Hematopoiesis and Cell Growth

    Investigators studied the two protein isoforms of T cell acute lymphoblastic leukemia protein 1 (TAL1), short and long, which were generated by the use of alternative promoters as well as by alternative splicing.
    [PLOS One]

    Full Article

    Effective Treatment with the Selective Cytokine Inhibitor BNZ-1 Reveals the Cytokine Dependency of T-LGL Leukemia

    Scientists conducted a Phase I/II trial of BNZ-1 in patients with T-LGLL who had hematocytopenias that required therapy. Clinical responses were assessed using hematologic parameters based off response criteria from the ECOG 5998 T-LGLL trial.
    [Blood]

    Abstract

    Allogeneic Hematopoietic Cell Transplantation for Patients with AML Aged 70 Years or Older in First Remission. A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (Ebmt)

    Investigators reported on the clinical outcomes of 701 adults aged ≥70 years, with AML in first complete remission, who received a first hematopoietic cell transplantation, from HLA-matched sibling donors, 10/10 HLA-matched unrelated donors, 9/10 HLA-mismatched unrelated donors or haploidentical donors.
    [Bone Marrow Transplantation]

    Abstract
    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    REVIEWS

    The Hematopoietic Microenvironment: A Network of Niches for the Development of All Blood Cell Lineages

    The authors discuss recent advances in the cellular identity and structural organization of lymphoid, granulocytic, monocytic, megakaryocytic, and erythroid niches throughout the hematopoietic microenvironment, and the mechanisms by which they interconnect and regulate developing blood cells.
    [Journal Of Leukocyte Biology]

    Abstract
    Graphical Abstract
    INDUSTRY AND POLICY NEWS

    US Food and Drug Administration Approves BioMarin’s Roctavian™ (Valoctocogene Roxaparvovec-Rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A

    BioMarin Pharmaceutical Inc. announced that the US FDA approved ROCTAVIAN™ gene therapy for the treatment of adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.
    [BioMarin Pharmaceutical, Inc.]

    Press Release
    FEATURED EVENT

    Integrative Molecular Epidemiology Workshop: Bridging Cancer Biology and Precision Medicine

    July 24 – 28, 2023
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Technical Assistant – Hematopoiesis and Leukemia

    St. Anna Children’s Cancer Research Institute – Vienna, Austria

    Professor – Hematology & Oncology

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Associate Professor – Pediatric Blood and Marrow Transplantation

    Fred Hutchinson Cancer Center – Seattle, Washington, United States

    Postdoctoral Research Associate – Hematopoietic Stem and Progenitor cells

    University Hospital RWTH Aachen – Aachen, Germany

    Postdoctoral Fellow – Medicinal Chemistry

    University of Michigan – Ann Arbor, Michigan, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter